US 7227010
Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
granted A61KA61K39/00A61K39/08
Quick answer
US patent 7227010 (Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy) held by The United States of America as represented by the Secretary of the Army expires Mon May 31 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America as represented by the Secretary of the Army
- Grant date
- Tue Jun 05 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 31 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61K, A61K39/00, A61K39/08